High serum level of plasminogen activator inhibitor-1 predicts histological grade of intracerebral gliomas

Anticancer Res. Jan-Feb 2008;28(1B):415-8.

Abstract

Background: No serum marker is currently available for the diagnosis and treatment of gliomas. Plasminogen activator inhibitor-1 (PAI-1) controls the proteolytic activity in cancer cells and cellular migration during angiogenesis.

Patients and methods: To verify the potential of PAI-1 as a serum marker for gliomas, the serum PAI-1 concentrations were measured by ELISA in 57 glioma patients and 34 healthy volunteers.

Results: We found significantly higher serum levels in the patients with high-grade gliomas than in the healthy volunteers (p = 0.0009, unpaired t-test) and those with low-grade tumors (p = 0.0074). Furthermore, high-grade glioma patients with a low serum level of PAI-1 survived significantly longer than those with high levels (p = 0.0082). Immunohistochemical analysis using anti-PAI-1 antibody revealed dense and spotty staining in the high-grade tumor tissues from the patients with high serum PAI-1 levels.

Conclusion: These results suggest that the serum PAI-1 level can be a marker for the prediction of histological grade in intracerebral glioma.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Biomarkers, Tumor / biosynthesis
  • Biomarkers, Tumor / blood
  • Brain Neoplasms / blood*
  • Brain Neoplasms / pathology
  • Female
  • Glioma / blood*
  • Glioma / pathology
  • Humans
  • Immunohistochemistry
  • Male
  • Middle Aged
  • Plasminogen Activator Inhibitor 1 / biosynthesis
  • Plasminogen Activator Inhibitor 1 / blood*

Substances

  • Biomarkers, Tumor
  • Plasminogen Activator Inhibitor 1